Recent

% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

crazyness42003 3 posts  |  Last Activity: 19 hours ago Member since: Feb 18, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • * Short Interest going down 1M+/mo
    * Multiple News worthy events on the horizon
    * High M&A activitiy in the biotech sector
    * Institutions accumulating in mass
    * Low volume
    * Very large after hours swings
    * If I were short I'd be very affraid, looking at the recent M&A activity you know we are in the ball park of $4 to $7 Billion take over range at least! That calls for a $16 to $29 price target. Institutions know this, HF know this, MM know this hence the constant hit pieces, frequent reposting of Zacks ratings by fictious blogs over the last serveral months, and deflated share price based on so called earnings.

    You look at any of the biotechs that have NO EARNINGs, and the institutions own over 90%. The stock prices are 40-60 times any revenue. Their pipelines are not as extensive as ARNA.

    They (MM), will hold this price down as long as it takes so there institutional buddies acquire 90% of the stock. Once this is achieved, they will artificially inflate the price above your wildest imagination. This is text book biotech manipulation. You just have to hold on through the storms, lies, hit pieces, speculation, etc.

    GLTAL; BS-B

  • * Short Interest going down 1M+/mo
    * Multiple News worthy events on the horizon
    * High M&A activitiy in the biotech sector
    * Institutions accumulating in mass
    * Low volume
    * Very large after hours swings
    * If I were short I'd be very affraid, looking at the recent M&A activity you know we are in the ball park of $4 to $7 Billion take over range at least! That calls for a $16 to $29 price target. Institutions know this, HF know this, MM know this hence the constant hit pieces, frequent reposting of Zacks ratings by fictious blogs over the last serveral months, and deflated share price based on so called earnings.

    You look at any of the biotechs that have NO EARNINGs, and the institutions own over 90%. The stock prices are 40-60 times any revenue. Their pipelines are not as extensive as ARNA.

    They (MM), will hold this price down as long as it takes so there institutional buddies acquire 90% of the stock. Once this is achieved, they will artificially inflate the price above your wildest imagination. This is text book biotech manipulation. You just have to hold on through the storms, lies, hit pieces, speculation, etc.

  • (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization.

    The FDA, in a warning on its website, said the medicines may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones.

    The oral drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine. They include AstraZeneca's Farxiga (dapagliflozin), J&J's Invokana (canagliflozin) and Jardiance (embagliflozin) from Lilly and Boehringer
    The medicines became popular in part because in addition to controlling blood sugar levels, they led to modest weight loss and slightly lower blood pressure. Obesity is a leading cause of type 2 diabetes and some older treatments cause weight gain.

    But the new FDA warning could help boost sales of alternative medicines, such as ..........

ABT
50.50-0.19(-0.37%)Aug 3 4:01 PMEDT